Rare disease experts
Having previously transformed a startup into a multi-million dollar pharmaceutical company, the Ambrose team is now focussing on sustainable access to life-changing drug treatments for rare disease patients.
Our team
Founder & CEO
Toby Wilson Waterworth
Toby has led and been part of leadership teams in multiple life science companies that have generated close to $1 billion in shareholder value. His 30 years of experience in North America, Europe, UK and the Middle East includes founding Atlantic Healthcare, which delivered 30x value for early investors, plus senior roles at HD Clinical, Expedeon, Alizyme and Chiroscience. Toby is a Fellow of the Royal Society of Medicine and a Fellow of the Institute of Chartered Accountants in England & Wales.
CFO
Peter McGowan
Peter specializes in strong financial disciplines and establishing new ventures, particularly in life sciences and technology. His 30 years of international experience includes serving as CFO for five different biotechnology companies with a focus on fundraising and closing business development deals. Previously, Peter held senior global finance positions at Mundipharma and PPD. He is a Fellow of the Association of Chartered Certified Accountants.
Corporate Communicatons
Juliet Burns
Juliet is a multi-lingual communications professional focused on helping growing rare diseases companies communicate effectively. With more than 15 years experience across Europe and the USA working on clinicial trial recruitment and disease awareness campaigns, academic symposia, corporate communications, and product development for patient platforms, she has extensive experience across all ends of healthcare. She has delivered projects for big pharma, but as an all-rounder she’s most passionate about supporting entrepreneurial teams and new businesses.
Founder & COO
Georgia Wilson Waterworth
Georgia has over 10 years of experience in the health and life sciences sector, both in start-ups and medium sized organisations, focusing on leadership and operations. Georgia has worked alongside the team at their previous company, after which she founded and exited her own healthcare company.
Manufacturing
Mike Webb
Mike specializes in chemistry, manufacturing and controls (CMC) in drug development, from late discovery to launch and beyond. He has been involved in eight worldwide marketing submissions and led departments of up to 150 scientists in a 30-year career at GSK. Mike has a PhD in analytical chemistry from Imperial College London.
Our medical advisory board
Canada
Professor Brian Feagan
Professor of Medicine at the Schulich School of Medicine & Dentistry, Ontario Dr Brian Feagan, a Gastroenterologist and Professor of Medicine, has dedicated his research to developing outcome measures for novel therapeutics and conducting large-scale multi-center clinical trials. With over 30 years of experience, he has authored over 550 articles, served as a Principal Investigator on more than 140 clinical trials and been named one of the top five experts globally for Crohn’s disease.
UK
Dr Shabbir Moochhala
Consultant Nephrologist and Physician, Royal Free Hospital Dr Shabbir Moochhala is an experienced consultant nephrologist at the Royal Free Hospital in London. He has specialist expertise in rare diseases and is a principal investigator for several international medical trials. He lectures internationally and leads in rare kidney disease at national level, including as chair of an NHS Rare Disease Collaborative Network in rare kidney stone disease.
UK
Dr Jamie Duckers
National Clinical Lead for Rare Disease, NHS Wales Dr Jamie Duckers, a Respiratory Physician, has made significant contributions to healthcare and research in Wales. He serves as the National Clinical Lead for Rare Disease, Wales, and research lead for the  All-Wales Adult Cystic Fibrosis Service, and is actively involved in various advisory groups related to cystic fibrosis and respiratory health. His experience also encompasses exploring early stakeholder engagement to ensure rare diseases patient priorities are being met early in the development of new drugs.
UK
Professor Kevin Mills
Head of the Translational and Clinical Omics Group at University College London based at the Great Ormond Street Institute of Child Health Professor Mills’ research aims to combine state-of-the-art technology with AI/Machine Learning to find new drug targets, identify new biomarkers and develop new and more precise tests. His research group is unique in that they can use their omic capability to help understand disease mechanisms and identify drug targets but can also translate any biomarker into a test to NHS or Industry accredited standards.